Journal article
Immunostimulatory CpG Oligodeoxynucleotides Enhance the Immune Response to Vaccine Strategies Involving Granulocyte-Macrophage Colony-Stimulating Factor
Blood, Vol.92(10), pp.3730-3736
11/15/1998
DOI: 10.1182/blood.V92.10.3730
PMID: 9808567
Abstract
Abstract Immunostimulatory oligodeoxynucleotides containing the CpG motif (CpG ODN) can activate various immune cell subsets and induce production of a number of cytokines. Prior studies have demonstrated that both CpG ODN and granulocyte-macrophage colony-stimulating factor (GM-CSF) can serve as potent vaccine adjuvants. We used the 38C13 murine lymphoma system to evaluate the immune response to a combination of these two adjuvants. Immunization using antigen, CpG ODN, and soluble GM-CSF enhanced production of antigen-specific antibody and shifted production towards the IgG2a isotype, suggesting an enhanced TH1 response. This effect was most pronounced after repeat immunizations with CpG ODN and antigen/GM-CSF fusion protein. A single immunization with CpG ODN and antigen/GM-CSF fusion protein 3 days before tumor inoculation prevented tumor growth. CpG ODN enhanced the production of interleukin-12 by bone marrow-derived dendritic cells and increased expression of major histocompatibility complex class I and class II molecules, particularly when cells were pulsed with antigen/GM-CSF fusion protein. We conclude that the use of CpG ODN in combination with strategies involving GM-CSF enhances the immune response to antigen and shifts the response towards a TH1 response and that this approach deserves further evaluation in tumor immunization approaches and other conditions in which an antigen-specific TH1 response is desirable.
Details
- Title: Subtitle
- Immunostimulatory CpG Oligodeoxynucleotides Enhance the Immune Response to Vaccine Strategies Involving Granulocyte-Macrophage Colony-Stimulating Factor
- Creators
- Hsin-Ming Liu - From the University of Iowa Interdisciplinary Graduate Program in Immunology, University of Iowa Department of Internal Medicine, University of Iowa Cancer Center, and Iowa City Veterans Affairs Medical Center, Iowa City, IASally E Newbrough - From the University of Iowa Interdisciplinary Graduate Program in Immunology, University of Iowa Department of Internal Medicine, University of Iowa Cancer Center, and Iowa City Veterans Affairs Medical Center, Iowa City, IASudershan K Bhatia - From the University of Iowa Interdisciplinary Graduate Program in Immunology, University of Iowa Department of Internal Medicine, University of Iowa Cancer Center, and Iowa City Veterans Affairs Medical Center, Iowa City, IAChristopher E Dahle - From the University of Iowa Interdisciplinary Graduate Program in Immunology, University of Iowa Department of Internal Medicine, University of Iowa Cancer Center, and Iowa City Veterans Affairs Medical Center, Iowa City, IAArthur M Krieg - From the University of Iowa Interdisciplinary Graduate Program in Immunology, University of Iowa Department of Internal Medicine, University of Iowa Cancer Center, and Iowa City Veterans Affairs Medical Center, Iowa City, IAGeorge J Weiner - From the University of Iowa Interdisciplinary Graduate Program in Immunology, University of Iowa Department of Internal Medicine, University of Iowa Cancer Center, and Iowa City Veterans Affairs Medical Center, Iowa City, IA
- Resource Type
- Journal article
- Publication Details
- Blood, Vol.92(10), pp.3730-3736
- DOI
- 10.1182/blood.V92.10.3730
- PMID
- 9808567
- ISSN
- 0006-4971
- eISSN
- 1528-0020
- Language
- English
- Date published
- 11/15/1998
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Pharmaceutical Sciences and Experimental Therapeutics; Radiation Oncology; Internal Medicine
- Record Identifier
- 9984094729102771
Metrics
8 Record Views